Each tablet contains Nebivolol 5 mg + Hydrochlorothiazide 12.5 mg.

Nebilong-H Tablets combine Nebivolol, a highly selective beta1-adrenergic receptor blocker, with Hydrochlorothiazide, a thiazide diuretic, to provide effective once-daily control of blood pressure. Nebivolol reduces heart rate, cardiac output, sympathetic nervous system activity, and peripheral vascular resistance, while Hydrochlorothiazide promotes sodium and water excretion, reducing plasma volume and vascular resistance. This complementary combination offers sustained antihypertensive efficacy and improves long-term blood pressure management.

Nebilong-H Tablets are indicated for the treatment of essential hypertension in adults requiring combination antihypertensive therapy.

Nebivolol lowers blood pressure through multiple mechanisms, including reduction of heart rate, decreased myocardial contractility, suppression of sympathetic nervous system activity, inhibition of renin release, vasodilation, and reduction of peripheral vascular resistance. Hydrochlorothiazide acts on the distal renal tubules by inhibiting the reabsorption of sodium and chloride ions, thereby increasing urinary excretion of sodium, chloride, and water. This diuretic effect decreases plasma volume and contributes to sustained blood pressure reduction. The combination provides additive antihypertensive effects through complementary cardiovascular and renal mechanisms.

The recommended dosage is one tablet once daily in the morning, or as directed by the physician. The tablet should be taken consistently at the same time each day to ensure optimal blood pressure control.

Nebilong-H Tablets are contraindicated in patients with known hypersensitivity to Nebivolol, Hydrochlorothiazide, or any component of the formulation, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome unless a permanent pacemaker is in place, severe hepatic impairment, and anuria.